Abstract
Histone deacetylases (HDACs) play a key role in the homeostasis of histone acetylation and gene transcription. Histone hypoacetylation and transcriptional dysfunction have been identified in a large number of neurological diseases, including ischemic and hemorrhagic stroke. HDAC inhibitors (HDACi) have emerged as a promising therapeutic intervention in neurodegenerative disorders. Here we review and discuss recent observations in the application of the HDACi to combat the effects of stroke in animal and cell culture models. These agents raise histone acetylation levels, adjust the transcription of associated genes, and exert neuroprotective benefits against stroke. Clinical randomized trials should be performed to further investigate the benefits of HDACi for stroke patients.
Keywords: Histone deacetylase inhibitors, stroke, histone, histone deacetylase (HDAC), histone acetyltransferase (HAT), valproic acid (VPA), sodium butyrate (SB), sodium phenylbutyrate (NaPB), trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), neuroprotection, chromatin, intracerebral hemorrhage (ICH), cerebral ischemia (CI), apoptosis, neuroinflammation, excitotoxicity, oxidative stress, neurotrophin, neurogenesis, histone acetylation, clinical randomed trial (RCT), central nervous system (CNS), brain edema, epidemiology
Central Nervous System Agents in Medicinal Chemistry
Title: Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Volume: 11 Issue: 2
Author(s): Lei Lv, Yu-Ping Tang, Xiang Han, Xin Wang and Qiang Dong
Affiliation:
Keywords: Histone deacetylase inhibitors, stroke, histone, histone deacetylase (HDAC), histone acetyltransferase (HAT), valproic acid (VPA), sodium butyrate (SB), sodium phenylbutyrate (NaPB), trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), neuroprotection, chromatin, intracerebral hemorrhage (ICH), cerebral ischemia (CI), apoptosis, neuroinflammation, excitotoxicity, oxidative stress, neurotrophin, neurogenesis, histone acetylation, clinical randomed trial (RCT), central nervous system (CNS), brain edema, epidemiology
Abstract: Histone deacetylases (HDACs) play a key role in the homeostasis of histone acetylation and gene transcription. Histone hypoacetylation and transcriptional dysfunction have been identified in a large number of neurological diseases, including ischemic and hemorrhagic stroke. HDAC inhibitors (HDACi) have emerged as a promising therapeutic intervention in neurodegenerative disorders. Here we review and discuss recent observations in the application of the HDACi to combat the effects of stroke in animal and cell culture models. These agents raise histone acetylation levels, adjust the transcription of associated genes, and exert neuroprotective benefits against stroke. Clinical randomized trials should be performed to further investigate the benefits of HDACi for stroke patients.
Export Options
About this article
Cite this article as:
Lv Lei, Tang Yu-Ping, Han Xiang, Wang Xin and Dong Qiang, Therapeutic Application of Histone Deacetylase Inhibitors for Stroke, Central Nervous System Agents in Medicinal Chemistry 2011; 11 (2) . https://dx.doi.org/10.2174/187152411796011330
DOI https://dx.doi.org/10.2174/187152411796011330 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Gut-Brain Axis, Including the Microbiome, Leaky Gut and Bacterial Translocation: Mechanisms and Pathophysiological Role in Alzheimer’s Disease
Current Pharmaceutical Design Fullerenes: From Carbon to Nanomedicine
Mini-Reviews in Medicinal Chemistry Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Mitochondrial Permeability Transition Pore as a Suitable Targ e t for Neuroprotective Agents Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems
Current Medicinal Chemistry Current Approaches for the Treatment with Thyroid Hormone Analogs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Editorial [Hot topic: Endocannabinoid Signaling and Neuroinflammatory Diseases (Executive Editor: Mauro Maccarrone)]
Current Pharmaceutical Design Inhibition of Disulfide Reductases as a Therapeutic Strategy
Current Enzyme Inhibition Quantitative and Mechanistic Studies of Aβ Immunotherapy
CNS & Neurological Disorders - Drug Targets Looking Towards New Pathogenetic Mechanisms in Parkinson’s Disease: is ANT1 the Potential Candidate?
Current Aging Science Emerging and Alternative Therapies For Parkinson Disease: An Updated Review
Current Pharmaceutical Design Commentary (Research Highlights)
CNS & Neurological Disorders - Drug Targets Catalpol: A Potential Therapeutic for Neurodegenerative Diseases
Current Medicinal Chemistry YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer’s Disease
Current Neuropharmacology Neurobiology of Alzheimer’s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions
Current Alzheimer Research <i>In-silico</i> Prediction of the Beta-carboline Alkaloids Harmine and Harmaline as Potent Drug Candidates for the Treatment of Parkinson’s disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nerve Growth Factor: Structure, Function and Therapeutic Implications for Alzheimers Disease
Current Drug Targets - CNS & Neurological Disorders NSAID Use and the Risk of Parkinsons Disease
Current Drug Safety Immunoregulatory Impact of Food Antioxidants
Current Pharmaceutical Design A Nanotechnological Approach to the Management of Alzheimer Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets